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This Month in the Journal
Haplotype Analysis of Drug-Related Genes, by
Kamatani et al. (p. 190)
The use of haplotype-tagging SNPs (htSNPs) has been
advocated by many as a way to minimize the genotyping
required in a linkage-disequilibrium study. An htSNP is
a SNP that can be used to mark the majority of haplo-
types in a segment of limited haplotype diversity. It has
been unclear, however, to what extent htSNPs represent
uncommon variation. Kamatani et al. study this in the
context of 199 genes involved in drug transport and/or
metabolism. They report that most uncommon SNPs
(those with minor-allele frequencies !0.1) can be identi-
ﬁed by htSNPs if the minor-allele frequencies of the un-
common SNPs are 1.03. This fact can be exploited to
detect uncommon, phenotype-associated SNPs by use of
the haplotype-tagging method, provided the uncommon
SNPs are located within a haplotype block—which was
the case for 160% of the uncommon SNPs in their
study—and provided the allele frequencies of the SNPs
differ between cases and controls. In their particular
study, this means that Kamatani et al. need to genotype
only 1,147 of 3,244 SNPs to perform a thorough case-
control association analysis within their set of 199 genes.
Ancient-DNA Statistics, by Spencer and Howe (p.
240)
One need only follow the Letters to the Editor section
of the Journal to know that the results of ancient-DNA
analyses are often controversial. Despite attempts to set
criteria for authentication, the results of these studies are
often disputed. Spencer and Howe advocate the use of
statistical methods to analyze the results of ancient DNA
studies. They propose one way to do this: a maximum-
likelihood method that allows them to calculate the prob-
ability that a positive result from a sample is authentic.
They can also calculate CIs for this probability. During
the study-design phase, their methods can be used to
determine the sample size necessary to achieve a given
level of conﬁdence. In fact, Spencer and Howe show that
it is essential to have more than a single sample to reject
the possibility that a positive result is due to contami-
nation. In these cases, even in the absence of positive
results from negative controls, the lower 95%CL is zero.
With ﬁve positive samples, on the other hand, the lower
CL goes up to 0.96. Their methods can also be used to
analyze results that have already been obtained. They ﬁnd
that positive results in negative control samples do not
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necessarily lead to rejection of the experiment. Instead,
these data can be taken into account when the probability
is calculated that a result is due to contamination.
GJA12 Mutations Cause PMLD, by Uhlenberg et al.
(p. 251)
Some people with a phenotype that is pretty much iden-
tical to Pelizaeus-Merzbacher disease (PMD) don’t have
mutations in the PMD gene PLP1 and have been lumped
in the category of having PMD-like disease (PMLD). Both
PMD and PMLD are characterized by such symptoms
as rapid, involuntary movements of the eye (nystagmus),
impaired motor development, ataxia, and difﬁculty ar-
ticulating. Uhlenberg et al. now report that at least some
people with PMLD have mutations in the gene encoding
the gap junction protein a12 (GJA12; connexin 46.6).
So what is the connection between PLP1 and GJA12?
PLP1 encodes themajor component ofmyelin in theCNS.
PMD-associated deletions of PLP1 lead to length-depen-
dent axonal degeneration, probably due to disruptions
of axonal-glial interactions (Garbern et al. [2002] Brain
125:551–561). In mice, Gja12 is expressed speciﬁcally in
oligodendrocytes in a pattern similar to Plp1 and other
myelin-related genes (Menichella et al. [2003] J Neurosci
23:5963–5973). It is largely colocalized with Cx32 in
oligodendrocytes, and these proteins appear to have a
similar and at least partially redundant function. Mice
that are double knockouts for Gja12 and Cx32 exhibit
tremors and seizure due to demyelination and oligoden-
drocyte cell death. The phenotype in these mice was used
to argue that gap-junction communication is required
for proper myelination. Not only does this ﬁnding begin
to explain that the underlying connection between PMD
and PMLD is due to defects in myelination in the CNS,
but it also brings another nervous system disorder into
the picture, X-linked Charcot-Marie-Tooth (CMTX).
CMTX is caused by mutations in the gene for GJA12’s
gap junction partner, CX32. Further highlighting the in-
tertwined nature of these disorders is the ﬁnding by Uhl-
enberg et al. that some of their patients with GJA12
mutations had peripheral neuropathy, which is a feature
of CMTX and is only sporadically found in PMD.
MCPH1 Regulates Chromosome Condensation, by
Trimborn et al. (p. 261)
Beyond the fact that it is mutated in some cases of pri-
mary microcephaly, little is known about the function of
microcephalin, MCPH1. The reduction in brain size in
affected individuals is believed to reﬂect a reduction in
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neural cells, as a result either of reduced cell proliferation
or of increased cell death. The phenotypic resemblance
between primary microcephaly and premature conden-
sation syndrome (PCC) led Trimborn et al. to postulate
that the disorders might be allelic. In fact, this turned out
to be true; they found a truncating MCPH1 mutation in
a family with PCC. An examination of the cellular phe-
notype of cells from patients with MCPH1 also sup-
ported the similarity of the disorders, which both show
low-quality metaphases with poor banding resolution,
a high proportion of prophaselike cells, and a consid-
erable delay in chromosome decondensation after mito-
sis. Loss of microcephalin is sufﬁcient to cause this cellu-
lar phenotype, as demonstrated through RNAi (RNA
interference)–mediated depletion of MCPH1. This work
reveals an early role for microcephalin in the regulation
of chromosome condensation. The authors propose, be-
cause of the homology between microcephalin and other
cell-cycle checkpoint proteins, that microcephalin may
act as an intermediary between cell-cycle control and the
chromosome-condensation apparatus. Ultimately, the
role that microcephalin plays in neurogenesis and the
explanation for the speciﬁcity of the primary micro-
cephaly and PCC phenotypes will need to be teased apart
as the precise function of microcephalin in these path-
ways is determined.
PTPN22 and Rheumatoid Arthritis, by Begovich et al.
(p. 330)
Genetic linkage of various autoimmune disorders to the
same loci and clustering of different autoimmune dis-
orders within families suggest that there are common
genetic underpinnings for autoimmunity. Along with a
recent paper by Bottini et al. (see reference in Begovich
et al.), Begovich et al. present evidence that one of the
“autoimmunity genes” may be PTPN22. This story
started when Bottini et al. reported a polymorphism in
PTPN22, which encodes a suppressor of T-cell activa-
tion, that is associated with type I diabetes (T1D). The
altered residue in the protein R620W lies in an N-ter-
minal proline-rich motif that interacts with Csk, which
in turn is a suppressor of Src kinases that mediate T-
cell–receptor signaling. A tryptophan residue in this mo-
tif interferes with binding to Csk and would presumably
lead to increased T-cell activity. In this issue, Begovich
et al. show that the association of PTPN22 is not limited
to T1D but can also be seen with another autoimmune
disorder, rheumatoid arthritis (RA). In two separate co-
horts, the same allele of PTPN22 was associated with
increased risk of RA. The authors further demonstrated,
through use of RNAi experiments, that PTPN22 does
function as a negative regulator of T-cell activation and,
through immunoprecipitations, that W620 PTPN22 may
not function properly because it does not bind Csk. Al-
though this would suggest a nice model for the devel-
opment of autoimmune disease on the basis of T-cell
hyperreactivity, PTPN22 is expressed in all subtypes of
peripheral-blood mononuclear cells, so the association
with RA may be multifactorial. Together, the results of
Bottini et al. and Begovich et al. suggest a common ge-
netic variant that contributes to the development of at
least two different autoimmune disorders.
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